The Medication Affordability and Patent Integrity Act aims to improve the affordability of medications and ensure the integrity of patents related to pharmaceuticals. This likely involves measures to reduce drug prices, increase access to medications for patients, and prevent practices that may extend patent protections unfairly, thus promoting competition in the pharmaceutical market.
Many media outlets have praised the Medication Affordability and Patent Integrity Act for its potential to lower prescription drug costs for consumers. Supporters argue that the bill addresses a critical need in the healthcare system by making medications more accessible, particularly for low-income families and those without insurance.
Critics of the Medication Affordability and Patent Integrity Act have raised concerns that the bill may undermine pharmaceutical innovation by limiting patent protections. Some argue that the legislation could discourage investment in research and development, leading to fewer new drugs entering the market and potentially harming long-term health outcomes.
The Medication Affordability and Patent Integrity Act, sponsored by Margaret Hassan, does not show any direct industry overlaps with her top donor industries, which include Health Professionals and Retired individuals. The total contributions from these sectors amount to $2.205 billion, but they do not directly relate to the pharmaceutical or medication affordability sectors that the bill addresses. While there is significant lobbying activity in the healthcare space, particularly from companies like Fresenius Kabi USA LLC, the absence of direct financial ties between the bill's subject matter and the sponsor's top donors suggests a low risk of conflict of interest. Voters should be aware that while there is lobbying present, it does not appear to directly influence the sponsor's legislative agenda based on the current data.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| FRESENIUS KABI USA LLC | FRESENIUS KABI USA LLC | $1,100,000 |
| CONSEJO COORDINADOR EMPRESARIAL | IQOM STRATEGIC ADVISORS, LLC | $140,000 |
| IVANHOE ATLANTIC (FORMERLY HIGH POWER EXPLORATION INC.) | YORKTOWN SOLUTIONS | $120,000 |
| SKYRYSE, INC. | SKYRYSE, INC. | $70,000 |
| AIS HEALTHCARE | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | $20,000 |
| THE FERGUSON GROUP, LLC ON BEHALF OF WEST COUNTY WASTEWATER DISTRICT, CA | EARL STOCKDALE | undisclosed |
| THE FERGUSON GROUP, LLC FOR CITY OF OCEANSIDE CA | EARL STOCKDALE | undisclosed |
| THE FERGUSON GROUP, LLC ON BEHALF OF WARD & SMITH (FOR BALD HEAD ISLAND) | EARL STOCKDALE | undisclosed |
| THE FERGUSON GROUP, LLC ON BEHALF OF WARD & SMITH, PA (FOR HOLDEN BEACH, NC) | EARL STOCKDALE | undisclosed |
| CORE POWER (US) INC. | INVARIANT LLC | undisclosed |
| ICON TECHNOLOGY, INC. | INVARIANT LLC | undisclosed |
| HUBBS-SEAWORLD RESEARCH INSTITUTE | HAMMER ASSOCIATES, LLC | undisclosed |
| THE POLICY SHOP LLC | JAVELIN ADVISORS LLC | undisclosed |
| NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS | NATIONAL ALLIANCE OF HEALTHCARE PURCHASER COALITIONS | undisclosed |
| EARTHSHIP CORPORATION | RED DOOR CONSULTING, LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Margaret Hassan, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
